Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy

2010 ◽  
Vol 5 (3) ◽  
pp. 287-296 ◽  
Author(s):  
Rengin Aslıhan Kurt ◽  
Ömür Ucakhan-Gündüz ◽  
Kaan Gündüz
Keyword(s):  
Ophthalmic Solution ◽  
Ocular Allergy

scholarly journals Evaluating Clinical Perceptions of a New Medication for Ocular Itch Associated with Allergic Conjunctivitis—Results of the Bepreve® 1.5% First Experience Field Survey

2011 ◽  
Vol 04 (01) ◽  
pp. 69
Author(s):  
Jai G Parekh ◽  
Keyword(s):  
Clinical Trial ◽  
Survey Data ◽  
Allergic Conjunctivitis ◽  
Field Survey ◽  
Ophthalmic Solution ◽  
Patient Experiences ◽  
Ocular Allergy ◽  
Over The Counter ◽  
Professional Evaluation ◽  
Clinical Trial Results

Allergic conjunctivitis associated with seasonal or perennial allergy is an increasingly prevalent complaint. Patients seeking professional evaluation for symptoms of ocular allergy usually have exhausted over-the-counter options and expect rapid, effective relief from the treatment prescribed. With the introduction of Bepreve® (bepotastine besilate ophthalmic solution) 1.5%, a survey of US doctors was conducted to evaluate their opinions and impressions of the medication following the initial patient trial. Responses from 427 practitioners, representing a total of 7,340 patient experiences, suggest that Bepreve is a rapidly effective and comfortable treatment. Nearly all respondents reported being satisfied or very satisfied with the performance of Bepreve. These survey data from the office setting are consistent with clinical trial results demonstrating that Bepreve provides rapid, durable, and comfortable relief of ocular itch.

The Expanding Picture of the Clinical Utility of BEPREVE® (Bepotastine Besilate Ophthalmic Solution) 1.5 % in the Treatment of Itch Associated with Allergic Conjunctivitis

2011 ◽  
Vol 04 (02) ◽  
pp. 101
Author(s):  
Richard L Lindstrom ◽  
Keyword(s):  
Allergic Conjunctivitis ◽  
Clinical Utility ◽  
Therapeutic Response ◽  
Ophthalmic Solution ◽  
Trial Data ◽  
Ocular Allergy ◽  
Pivotal Trial ◽  
Exposure Study ◽  
Fda Approval ◽  
Ocular Itching

A new analysis of pivotal trial data and a variety of additional studies completed since US Food and Drug Administration (FDA) approval are broadening our understanding of the clinical utility of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5 % in the treatment of ocular itch associated with allergic conjunctivitis. These results include evidence of a durable therapeutic response of up to 16 hours following a single dose, a comfort profile comparable or superior to other drugs in the class, and robust efficacy against ocular itching and redness in an environmental exposure study model that simulates the patient experience of ocular allergy.

Development and Validation of a Novel Reversed Phase High Performance Liquid Chromatography with Refractive Index Detector Method for Assay of Polyvinyl Alcohol in an Ophthalmic Solution

2020 ◽  
Vol 16 (7) ◽  
pp. 867-871
Author(s):  
Harun Ergen ◽  
Muge Guleli ◽  
Cigdem Sener ◽  
Cem Caliskan ◽  
Sercan Semiz ◽  
...  
Keyword(s):  
Refractive Index ◽  
Liquid Chromatography ◽  
Polyvinyl Alcohol ◽  
High Performance ◽  
Ophthalmic Solution ◽  
Reversed Phase ◽  
Hplc Method ◽  
Solution Stability ◽  
Technical Requirements ◽  
Refractive Index Detector

Introduction: Polyvinyl alcohol (PVA), a polymer, is in demand due to its usage in different applications such as pharmaceutical, biomedical and textile, paper, food industries. Methods: A new sensitive reversed phased high-pressure liquid chromatography (RP-HPLC) method with refractive index detector (RID) was developed for determination of PVA in an ophthalmic solution containing dexpanthenol and PVA as active substances and it was validated according to The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline. Results: Chromatographic separation was achieved on a Chiral-AGP (150 mm × 4.0 mm, 5 μm) column kept at 30°C with an isocratic flow at a flow rate of 1.0 ml/min. The detector temperature was 30°C, the retention time of PVA was around 1.0 min and the total run time was 5 minutes. Conclusion: The proposed method showed linearity, accuracy, precision, specificity, robustness, solution stability, and system suitability results within the acceptance criteria.

scholarly journals Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Takehiro Matsumura ◽  
Kentaro Iwasaki ◽  
Shogo Arimura ◽  
Ryuji Takeda ◽  
Yoshihiro Takamura ◽  
...  
Keyword(s):  
Growth Factor ◽  
Inflammatory Cytokines ◽  
Aqueous Humour ◽  
Ophthalmic Solution ◽  
Vascular Endothelial ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Before And After ◽  
Endothelial Growth Factor ◽  
Single Blind

AbstractIntraocular surgery is associated with increased ocular inflammation. If maintained for a prolonged period after surgery, this inflammation can cause various complications, including subconjunctival fibrosis and bleb scarring. This clinical trial was a prospective, randomised, single-blind, interventional study comparing the efficacy and safety of 0.1% bromfenac sodium ophthalmic solution and 0.02% fluorometholone ophthalmic suspension in the inhibition of multiple inflammatory cytokines in the aqueous humour of 26 patients with pseudophakic eyes who had undergone phacoemulsification and intraocular lens implantation. The patients were randomly assigned to one of the trial drugs, and aqueous humour samples were collected before and after drug administration. Platelet-derived growth factor-AA levels significantly decreased in both drug groups, but they were significantly higher in the fluorometholone group than in the bromfenac group (P = 0.034). Bromfenac also significantly decreased vascular endothelial growth factor level (P = 0.0077), as well as monocyte chemoattractant protein-1 level (P = 0.013), which was elevated for a prolonged period after phacoemulsification. These data suggest that bromfenac is useful to alleviate prolonged microenvironmental alterations in the aqueous humour of pseudophakic eyes.

scholarly journals Ocular allergy latin american consensus

2011 ◽  
Vol 74 (6) ◽  
pp. 452-456 ◽  
Author(s):  
Myrna Serapião dos Santos ◽  
Milton Ruiz Alves ◽  
Denise de Freitas ◽  
Luciene Barbosa de Sousa ◽  
Ricardo Wainsztein ◽  
...  
Keyword(s):  
Latin American ◽  
Ocular Allergy
Sign in / Sign up

Export Citation Format

Share Document